Method for enhancing mammalian immunological function
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 60/711,415, filed Aug 26, 2005. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,427,449 | Binding of GALECTIN-3 by Low Molecular Weight Pectin In force · High confidence | Econugenics, Inc. | In force | High confidence | ||
| US 8,426,567 | Method for enhancing mammalian immunological function In force · High confidence | Econugenics, LLC | In force | High confidence | ||
| US 8,916,541 | Anti-Cancer Regimen In force · High confidence | Econugenics, LLC | In force | High confidence | ||
| US 9,649,329 | Binding of GALECTIN-3 by Low Molecular Weight Pectin Term ended Term ended Jul 14, 2026 · High confidence | Econugenics, LLC | Term ended | Term ended Jul 14, 2026 | High confidence | |
| US 10,555,966 | Binding of Galectin-3 By Low Molecular Weight Pectin Term ended Term ended Jul 14, 2026 · High confidence | Econugenics, LLC | Term ended | Term ended Jul 14, 2026 | High confidence |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Econugenics LLC.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.